Cargando…

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

RATIONALE: C-reactive protein (CRP) is a systemic marker of inflammation that correlates with disease status in cystic fibrosis (CF). The clinical utility of CRP measurement to guide pulmonary exacerbation (PEx) treatment decisions remains uncertain. OBJECTIVES: To determine whether monitoring CRP d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Ashutosh, Kirkpatrick, Gordon, Chen, Virginia, Skolnik, Kate, Hollander, Zsuzsanna, Wilcox, Pearce, Quon, Bradley S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298271/ https://www.ncbi.nlm.nih.gov/pubmed/28178305 http://dx.doi.org/10.1371/journal.pone.0171229

Ejemplares similares

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
por: Skolnik, Kate, et al.
Publicado: (2018)

Nontuberculous Mycobacteria in Cystic Fibrosis
por: Skolnik, Kate, et al.
Publicado: (2016)

Plasma sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis
por: Quon, Bradley S., et al.
Publicado: (2014)

Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis
por: Lin, Ann Hsu-An, et al.
Publicado: (2017)

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
por: Sergeev, Valentine, et al.
Publicado: (2020)

Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review
por: Nguyen, Anna-Lisa V., et al.
Publicado: (2022)

Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic
por: Goodwin, Jodi, et al.
Publicado: (2022)

Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre
por: Roberts, James M., et al.
Publicado: (2016)

A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
por: Habib, Al-Rahim R., et al.
Publicado: (2019)

Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics
por: Dong, Kang, et al.
Publicado: (2019)

Cystic Fibrosis Respiratory Microbiology Monitoring during a Global Pandemic: Lessons Learned from a Shift to Telehealth
por: Franciosi, Alessandro N., et al.
Publicado: (2022)

Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes
por: Lam, Grace Y., et al.
Publicado: (2021)

Optic Disc Swelling and Vision Loss in a Patient with Cystic Fibrosis and Diabetes
por: Iosfina, Ioulia, et al.
Publicado: (2013)

Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations
por: Merjaneh, Lina, et al.
Publicado: (2020)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
por: Wojsyk-Banaszak, I., et al.
Publicado: (2019)

Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
por: Hassanzad, Maryam, et al.
Publicado: (2021)

Nebulized levofloxacin for chronic Burkholderia cenocepacia pulmonary infection in cystic fibrosis: A case report
por: Dagenais, Renée VE., et al.
Publicado: (2022)

Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis
por: Quon, Bradley S., et al.
Publicado: (2020)

Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns
por: Desai, Sameer, et al.
Publicado: (2023)

Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis
por: Girón-Moreno, Rosa Maria, et al.
Publicado: (2014)

Glucose Tolerance during Pulmonary Exacerbations in Children with Cystic Fibrosis
por: Widger, John, et al.
Publicado: (2012)

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
por: DiMango, Emily, et al.
Publicado: (2014)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis
por: Asner, Sandra, et al.
Publicado: (2012)

BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
por: Schultz, Andre, et al.
Publicado: (2023)

Worsening pulmonary outcomes during sex reassignment therapy in a transgender female with cystic fibrosis (CF) and asthma/allergic bronchopulmonary aspergillosis: a case report
por: Lam, G. Y., et al.
Publicado: (2020)

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study
por: Wells, J. Michael, et al.
Publicado: (2016)

Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape
por: Stanford, Gemma E., et al.
Publicado: (2021)

Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care
por: Franciosi, Alessandro N., et al.
Publicado: (2022)

Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease
por: Quinn, Robert A., et al.
Publicado: (2016)

The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis
por: Al-Aloul, Mohamed, et al.
Publicado: (2019)

Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic Fibrosis
por: Meyer, Viviane Mauro Correa, et al.
Publicado: (2020)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation
por: Walicka-Serzysko, Katarzyna, et al.
Publicado: (2021)

Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations
por: Waters, Valerie
Publicado: (2021)

C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations
por: Matouk, Elias, et al.
Publicado: (2016)

TeleHealth or TeleWealth? Equity challenges for the future of cystic fibrosis care (Commentary)()
por: Franciosi, Alessandro N, et al.
Publicado: (2021)

Falling through the Cracks—The Impact of Care Gaps on Lung Function Loss in Cystic Fibrosis
por: Love, Allison J., et al.
Publicado: (2023)

IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations
por: Solomon, George M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fbfk056njhtqrh9iqfe8is15ah